title: Helicobacter Pylori and Gastric Cancer: Clinical Aspects.
abstract: OBJECTIVE
  Although Helicobacter pylori (H. pylori) is considered as the main etiological factor for gastric cancer, the strategy of screening and treating the oncogenic bacterium is still controversial. The objective was to evaluate the status and progress of the cognition about the relationship between H. pylori infection and gastric cancer from a clinical aspect.
  
  
  METHODS
  The data used in this review were mainly from the PubMed articles published in English from 1984 to 2015.
  
  
  METHODS
  Clinical research articles were selected mainly according to their level of relevance to this topic.
  
  
  RESULTS
  Gastric cancer is the fifth most common malignancy and the third leading cause of cancer deaths worldwide. The main etiological factor for gastric cancer is H. pylori infection. About 74.7-89.0% gastric cancer was related to H. pylori infection. Up to date, some regional gastric cancer prevention programs including the detection and treatment of H. pylori infection are under way. Current data obtained from the randomized controlled trials suggest that population-based H. pylori screening and treatment is feasible and cost-effective in preventing gastric cancer; however, a population-based H. pylori eradication campaign would potentially lead to bacterial resistance to the corresponding antibiotics, as well as a negative impact on the normal flora.
  
  
  CONCLUSIONS
  The important questions of feasibility, program costs, appropriate target groups for intervention, and the potential harm of mass therapy with antibiotics must first be answered before implementing any large-scale program.
authors.forename: Zhi-Qiang
authors.initials: ZQ
authors.lastname: Song
authors.affiliation: Department of Gastroenterology, Peking University Third Hospital, Beijing 100191, China.
authors.forename: Li-Ya
authors.initials: LY
authors.lastname: Zhou
mesh_terms: D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D003362:Cost-Benefit Analysis; D016481:Helicobacter Infections / Q000191:economics / Q000517:prevention & control*; D016480:Helicobacter pylori / Q000187:drug effects / Q000472:pathogenicity*; D006801:Humans; D008403:Mass Screening / Q000191:economics; D013274:Stomach Neoplasms / Q000382:microbiology* / Q000517:prevention & control*
chemical_list: D000900:Anti-Bacterial Agents